Literature DB >> 16315090

Production of two vaccinating recombinant rotavirus proteins in the milk of transgenic rabbits.

Eric Soler1, Agnès Le Saux, Frédéric Guinut, Bruno Passet, Ruxandra Cohen, Christine Merle, Annie Charpilienne, Cynthia Fourgeux, Véronique Sorel, Antoine Piriou, Isabelle Schwartz-Cornil, Jean Cohen, Louis-Marie Houdebine.   

Abstract

Rotaviruses are the main cause of infantile viral gastroenteritis worldwide leading to approximately 500,000 deaths each year mostly in the developing world. For unknown reasons, live attenuated viruses used in classical vaccine strategies were shown to be responsible for intussusception (a bowel obstruction). New strategies allowing production of safe recombinant non-replicating rotavirus candidate vaccine are thus clearly needed. In this study we utilized transgenic rabbit milk as a source of rotavirus antigens. Individual transgenic rabbit lines were able to produce several hundreds of micrograms per ml of secreted recombinant VP2 and VP6 proteins in their milk. Viral proteins expressed in our model were immunogenic and were shown to induce a significant reduction in viral antigen shedding after challenge with virulent rotavirus in the adult mouse model. To our knowledge, this is the first report of transgenic mammal bioreactors allowing the rapid co-production of two recombinant viral proteins in milk to be used as a vaccine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16315090     DOI: 10.1007/s11248-005-1771-0

Source DB:  PubMed          Journal:  Transgenic Res        ISSN: 0962-8819            Impact factor:   2.788


  43 in total

1.  Withdrawal of rotavirus vaccine recommendation.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1999-11-05       Impact factor: 17.586

2.  Serotype classification and characterisation of the rotavirus SA11 VP6 protein using mass spectrometry and two-dimensional gel electrophoresis.

Authors:  K R Emslie; M P Molloy; C R Barardi; D Jardine; M R Wilkins; A R Bellamy; K L Williams
Journal:  Funct Integr Genomics       Date:  2000-05       Impact factor: 3.410

3.  Functional mapping of protective domains and epitopes in the rotavirus VP6 protein.

Authors:  A H Choi; M Basu; M M McNeal; J Flint; J L VanCott; J D Clements; R L Ward
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice.

Authors:  Andrea Bertolotti-Ciarlet; Max Ciarlet; Sue E Crawford; Margaret E Conner; Mary K Estes
Journal:  Vaccine       Date:  2003-09-08       Impact factor: 3.641

5.  A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum.

Authors:  Anthony W Stowers; Li-how Chen Lh; Yanling Zhang; Michael C Kennedy; Lanling Zou; Lynn Lambert; Timothy J Rice; David C Kaslow; Allan Saul; Carole A Long; Harry Meade; Louis H Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

6.  Intranasal administration of an Escherichia coli-expressed codon-optimized rotavirus VP6 protein induces protection in mice.

Authors:  Anthony H-C Choi; Mitali Basu; Monica M McNeal; Judy A Bean; John D Clements; Richard L Ward
Journal:  Protein Expr Purif       Date:  2004-12       Impact factor: 1.650

7.  Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity.

Authors:  J W Burns; M Siadat-Pajouh; A A Krishnaney; H B Greenberg
Journal:  Science       Date:  1996-04-05       Impact factor: 47.728

8.  Oral immunization with rotavirus VP7 expressed in transgenic potatoes induced high titers of mucosal neutralizing IgA.

Authors:  Yu-Zhang Wu; Jin-Tao Li; Zhi-Rong Mou; Lei Fei; Bing Ni; Miao Geng; Zheng-Cai Jia; Wei Zhou; Li-Yun Zou; Yan Tang
Journal:  Virology       Date:  2003-09-01       Impact factor: 3.616

Review 9.  Transgenic rabbits as therapeutic protein bioreactors and human disease models.

Authors:  Jianglin Fan; Teruo Watanabe
Journal:  Pharmacol Ther       Date:  2003-09       Impact factor: 12.310

10.  Production of immunogenic VP6 protein of bovine group A rotavirus in transgenic potato plants.

Authors:  T Matsumura; N Itchoda; H Tsunemitsu
Journal:  Arch Virol       Date:  2002-06       Impact factor: 2.574

View more
  6 in total

1.  Gene-environment interactions influence ecological consequences of transgenic animals.

Authors:  L F Sundström; M Lõhmus; W E Tymchuk; Robert H Devlin
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-27       Impact factor: 11.205

2.  The construction and expression of lysine-rich gene in the mammary gland of transgenic mice.

Authors:  Xin Ma; Peng Zhang; Guangqi Song; Yue Chen; Zhongwei Wang; Yupeng Yin; Delong Kong; Sheng Zhang; Zhihui Zhao; Hongsheng Ouyang; Bo Tang; Ziyi Li
Journal:  DNA Cell Biol       Date:  2012-05-11       Impact factor: 3.311

Review 3.  Recombinant vaccines in 2022: a perspective from the cell factory.

Authors:  Marianna Teixeira de Pinho Favaro; Jan Atienza-Garriga; Carlos Martínez-Torró; Eloi Parladé; Esther Vázquez; José Luis Corchero; Neus Ferrer-Miralles; Antonio Villaverde
Journal:  Microb Cell Fact       Date:  2022-10-05       Impact factor: 6.352

4.  Immune response induced by spike protein from transmissible gastroenteritis coronavirus expressed in mouse mammary cells.

Authors:  Shu-Ying Peng; Ning Lv; Yong Zhang; Cong-Ming Bi; Jun-Wei Cao; Zhi-Yan Li; Shi-Qiang Zhang; Xiao-Ning He
Journal:  Virus Res       Date:  2007-05-25       Impact factor: 3.303

Review 5.  Preparation of recombinant vaccines.

Authors:  Eric Soler; Louis-Marie Houdebine
Journal:  Biotechnol Annu Rev       Date:  2007

Review 6.  Production of pharmaceutical proteins by transgenic animals.

Authors:  Louis-Marie Houdebine
Journal:  Comp Immunol Microbiol Infect Dis       Date:  2008-02-19       Impact factor: 2.268

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.